Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 15/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093084 | 0.89 | SYK (0.42) | SYKBTKHDAC1 | |
| SCHEMBL4090596 | 0.88 | SYK (0.48) | SYKBTKPOLBTDP1 | |
| SCHEMBL4096467 | 0.84 | SYK (0.39) | SYKBTKHDAC1 | |
| SCHEMBL4090528 | 0.81 | BTK (0.65) | SYKBTKSMN1; SMN2 | |
| SCHEMBL4091766 | 0.80 | BTK (0.58) | SYKBTK | |
| SCHEMBL4090445 | 0.80 | BTK (0.54) | SYKBTKALDH1A1SMN1; SMN2 | |
| SCHEMBL4084365 | 0.80 | SYK (0.52) | SYKALDH1A1RECQLSMN1; SMN2 | |
| SCHEMBL4086089 | 0.80 | BTK (0.52) | SYKBTKPOLBTDP1SMN1; SMN2 | |
| SCHEMBL4080605 | 0.79 | BTK (0.43) | SYKBTKPOLBTDP1HDAC1 | |
| SCHEMBL4095844 | 0.78 | BTK (0.51) | SYKBTKPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | claimed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | SYK 2/4885BTK 1/4885POLB 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.